drugset / Trial / NCT02919059
Study to Asses the Effect of Dapagliflozin on Central Blood Pressure Reduction.
RandomizedParallel-groupDouble-blindTreatment
Summary
This superiority of central pressure versus peripheral measures to predict cardiovascular events has also been reported in general population or in elder people
Timeline
- Start
- 2016-12-13
- Primary completion
- 2018-12
- Completion
- 2019-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dapagliflozin | Small molecule | 10 mg | — |
| Comparator | Glimepiride | Small molecule | 4 mg | — |